Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atosiban for Endometriosis-related Pain
NCT05382143Phase 2Unknown
- Sponsor
- Radboud University Medical Center
- Start
- Feb 2022
- Primary completion
- Jun 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atosiban in endometriosis, sponsored by Radboud University Medical Center. Primary endpoint: Difference in pain score (VAS) at 4 weeks. Status: unknown.
02
Drugs
atosiban
03
Conditions
endometriosis
Beyond the preview
Go deeper on NCT05382143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05382143.